Disclaimer

The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com. The DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe.

Investors

Analyst Coverage
Degroof Petercam

Laura Roba, Kris Kippers


Edison Investment Research

Pooya Hemami


H.C. Wainwright

Yi Chen, Raghuram Selvaraju


KBC Securities

Jeroen Van den Bossche


Van Lanschot Kempen

Suzanne van Voorthuizen


Kepler Cheuvreux

Arsene Guekam

Edison Research

Click here to receive Edison’s research on Sequana Medical in real-time

Any opinions, estimates or forecasts regarding Sequana Medical’s performance made by these analysts are those of the author and do not reflect the views of Sequana Medical and its management. Sequana Medical does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. To obtain a copy of their research reports, please contact their respective institutions.

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES